Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 02 10; 41(5):1105-1115.

View in: PubMed

subject areas

Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Erlotinib Hydrochloride
Humans
Lung Neoplasms
Mutation
Protein Kinase Inhibitors

authors with profiles

Everett E. Vokes